Ming Huang

Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study

Zhenggang Ren, Jianming Xu, Yuxian Bai et al. · The Lancet Oncology · 2021 · 1.1K citations

Medicine, Oncology, Pharmacology +13

Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2

Shiyu Yin, Ming Huang, Dengju Li et al. · Journal of Thrombosis and Thrombolysis · 2020 · 450 citations · Full text

Medicine, Infectious Diseases, Internal Medicine +14

Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001)

Hai‐Dong Zhu, Hai-Liang Li, Mingsheng Huang et al. · Signal Transduction and Targeted Therapy · 2023 · 283 citations · Full text

Pharmacy, Oncology, Pharmacology +17

Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: A multicentre observational study

Qiuhe Wang, Dongdong Xia, Wei Bai et al. · Journal of Hepatology · 2019 · 266 citations

Medicine, Oncology, Hepatology +13

Urine DNA methylation assay enables early detection and recurrence monitoring for bladder cancer

Xu Chen, Jingtong Zhang, Weimei Ruan et al. · Journal of Clinical Investigation · 2020 · 260 citations · Full text

Medicine, Oncology, Urology +17